{"title":"[Place of screening and genetic counseling in sickle cell disease].","authors":"Assa Niakaté, Marie-Hélène Odièvre","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21248,"journal":{"name":"Revue Du Praticien","volume":"73 5","pages":"531-534"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9982430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
SEXUAL HARASSMENT AT WORK. Sexist and sexual violence in the workplace may seem over-mediatized but it should no longer be ignored. These situations must be reported. French legislation requires the employer to prevent, act and sanction. The employee victim must be able to speak freely and know the actors in her/his efforts to be able to stop these actions but also to be accompanied. These actors are first and foremost the employer (the sexual harassment referent, staff representatives, human resources, management), the labor inspectorate, the defender of rights, the occupational physician, the attending physician and victim support associations. In any case, victims should be advised to speak up, not to remain isolated and to s eek help.
{"title":"[Sexual harassment at work].","authors":"Alexandra Salembier-Trichard, Pierre-Marie Wardyn","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>SEXUAL HARASSMENT AT WORK. Sexist and sexual violence in the workplace may seem over-mediatized but it should no longer be ignored. These situations must be reported. French legislation requires the employer to prevent, act and sanction. The employee victim must be able to speak freely and know the actors in her/his efforts to be able to stop these actions but also to be accompanied. These actors are first and foremost the employer (the sexual harassment referent, staff representatives, human resources, management), the labor inspectorate, the defender of rights, the occupational physician, the attending physician and victim support associations. In any case, victims should be advised to speak up, not to remain isolated and to s eek help.</p>","PeriodicalId":21248,"journal":{"name":"Revue Du Praticien","volume":"73 5","pages":"493-496"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9680512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
National advisory committee on ethics: FORTY YEARS OF BIOETHICS IN France. The history of the National Advisory Committee on Ethics for Life Sciences and Health (CCNE) shows its specificity, the evolution of its competences and its role in the institutional landscape of ethics in France, between independence and openness to the City. While constantly reaffirming its adherence to fundamental ethical principles, the CCNE has been marked by forty years of movements, crises and upheavals in the fields of health, science and society. What about tomorrow?
{"title":"[National Consultative Ethics Committee: forty years of bioethics in France!]","authors":"Jean-François Delfraissy, Clara Ruault","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>National advisory committee on ethics: </strong>FORTY YEARS OF BIOETHICS IN France. The history of the National Advisory Committee on Ethics for Life Sciences and Health (CCNE) shows its specificity, the evolution of its competences and its role in the institutional landscape of ethics in France, between independence and openness to the City. While constantly reaffirming its adherence to fundamental ethical principles, the CCNE has been marked by forty years of movements, crises and upheavals in the fields of health, science and society. What about tomorrow?</p>","PeriodicalId":21248,"journal":{"name":"Revue Du Praticien","volume":"73 5","pages":"477-480"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9982424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CANCER AND FERTILITY PRESERVATION. The integration of fertility preservation into the treatment pathway is a major issue for quality of life after cancer, particularly for very young children, adolescents and young adults. Responses must be adapted to age, gender and treatment. The recommendations of the French National Cancer Institute (INCa) aim to promote information on the risks of different treatments for fertility and on the possibilities of preserving fertility, in order to allow an informed choice, and to improve the quality of the medical service rendered in order to reduce inequalities in care. Referral to a center specialized in fertility preservation is sometimes recommended, so that a technique adapted to the patient's situation can be implemented before treatment begins.
{"title":"[Restatement. Cancer and fertility preservation].","authors":"Blandine Courbiere, Catherine Poirot, Christine Decanter, Nathalie Rives, Éric Huyghe","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>CANCER AND FERTILITY PRESERVATION. The integration of fertility preservation into the treatment pathway is a major issue for quality of life after cancer, particularly for very young children, adolescents and young adults. Responses must be adapted to age, gender and treatment. The recommendations of the French National Cancer Institute (INCa) aim to promote information on the risks of different treatments for fertility and on the possibilities of preserving fertility, in order to allow an informed choice, and to improve the quality of the medical service rendered in order to reduce inequalities in care. Referral to a center specialized in fertility preservation is sometimes recommended, so that a technique adapted to the patient's situation can be implemented before treatment begins.</p>","PeriodicalId":21248,"journal":{"name":"Revue Du Praticien","volume":"73 5","pages":"557-560"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9680517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
THERAPEUTIC APPROACHES IN SICKLE CELL DISEASE. Sickle cell disease, the most common genetic disease in France, is still burdened with morbidity and early mortality before the age of 50. When the first-line treatment, hydroxyurea, is insufficient or in the case of organic damage(s) (in particular cerebral vasculopathy), a therapeutic intensification must be considered. New molecules are now available, such as voxelotor and crizanlizumab, but only hematopoietic stem cell (HSC) transplantation can cure the disease. Allogeneic HSC transplantation during childhood with a sibling donor is the reference but it is now possible to perform this procedure in adults with a reduced pre-transplant conditioning. Gene therapy, which consists of an autograft of genetically modified HSCs, has obtained promising results but has not yet demonstrated a complete cure of the disease (protocols underway). The toxicity of myeloablative conditioning (used in pediatrics or for gene therapy), particularly the sterility induced, and the risk of graft-versushost disease (for allogeneic transplantation) are limiting factors of these treatments.
{"title":"[Therapeutic approaches in sickle cell disease].","authors":"Laure Joseph, Jean-Benoît Arlet, Françoise Bernaudin, Nathalie Dhédin","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>THERAPEUTIC APPROACHES IN SICKLE CELL DISEASE. Sickle cell disease, the most common genetic disease in France, is still burdened with morbidity and early mortality before the age of 50. When the first-line treatment, hydroxyurea, is insufficient or in the case of organic damage(s) (in particular cerebral vasculopathy), a therapeutic intensification must be considered. New molecules are now available, such as voxelotor and crizanlizumab, but only hematopoietic stem cell (HSC) transplantation can cure the disease. Allogeneic HSC transplantation during childhood with a sibling donor is the reference but it is now possible to perform this procedure in adults with a reduced pre-transplant conditioning. Gene therapy, which consists of an autograft of genetically modified HSCs, has obtained promising results but has not yet demonstrated a complete cure of the disease (protocols underway). The toxicity of myeloablative conditioning (used in pediatrics or for gene therapy), particularly the sterility induced, and the risk of graft-versushost disease (for allogeneic transplantation) are limiting factors of these treatments.</p>","PeriodicalId":21248,"journal":{"name":"Revue Du Praticien","volume":"73 5","pages":"535-539"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9680523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Anatomy, what we owe to Vesalius?]","authors":"Jean-Noël Fabiani-Salmon","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21248,"journal":{"name":"Revue Du Praticien","volume":"73 5","pages":"575-578"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9680514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Sickle cell disease: from a pediatric disease to an adult disease].","authors":"Bérengère Koehl, Geoffrey Cheminet","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21248,"journal":{"name":"Revue Du Praticien","volume":"73 5","pages":"513-515"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9680515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号